Valsartan and Hydrochlorothiazide tablets USP 80 mg/12 recalled over manufacturing violations
- Recall date
- December 31, 2018
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Aurobindo Pharma USA Inc. recalls Valsartan and Hydrochlorothiazide tablets USP 80 mg/12.5 mg, 90-count bottle, Rx Only, Manufactured for: Aurobindo Phar…
- Recall number
- D-0368-2019
- FDA classification
- Class II
- Brand / firm
- Aurobindo Pharma USA Inc.
- Sold / distributed
- Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout the United States.
Why it was recalled
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Valsartan and Hydrochlorothiazide tablets USP 80 mg/12.5 mg, 90-count bottle, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-547-90.
Get recall alerts
Free email alert whenever Aurobindo Pharma USA Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Aurobindo Pharma USA Inc.